Therapy News and Research

RSS

Researchers discover new way to stop cancer cells from spreading

Researchers at the Francis Crick Institute and the University of Copenhagen have discovered a new way to potentially 'fence in' a tumour and help stop cancer cells spreading, according to a Cancer Research UK funded study published in EMBO Reports today, (Thursday).

1 Oct 2015

Postmenopausal women who are not aware of VVA consequences continue to experience pain during sex

Results from qualitative research of postmenopausal women with vulvar and vaginal atrophy (VVA) show that they recognize the significant physical, emotional and psychological consequences of untreated dyspareunia (painful sex) yet they continue to suffer because of misperceptions about the condition and a general lack of understanding about treatment options.

1 Oct 2015

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

A vast number and variety of remedies are steadily joining the treatment pipeline for colorectal cancer. High incidence of the disease, unmet clinical needs, and huge commercial potential are attracting drug developers to the market.

1 Oct 2015

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Monteris Medical today announced recent data demonstrating that newly diagnosed brain tumor patients undergoing procedures with the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool, experienced improved outcomes.

1 Oct 2015

Research shows more than 30,000 women die from cardiovascular disease in UK

More than 30,000 women die from coronary heart disease in the UK every year with over 700,000 women living with the consequences of heart disease and stroke, according to research published by The British Heart Foundation ahead of World Heart Day on 29th September.

1 Oct 2015

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Almost half of patients with advanced lung cancer receive more than the recommended number of radiation treatments to reduce their pain, according to a new study published in the Journal of the National Cancer Institute.

1 Oct 2015

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

The results show that Oraya Therapy is effective in maintaining vision with reduced injections for patients at different stages of their disease—from chronic patients in discontinuous treatment to treatment-naive patients with new diagnosis—and following different treatment pathways.

1 Oct 2015

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers and published online today in the New England Journal of Medicine.

1 Oct 2015

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer-related deaths among men in the U.S. The challenge with prostate cancer is that the standard treatment methods in the advanced stage of the disease lose effectiveness after about one to two years, leading to recurrence and, ultimately, death. A University of Houston researcher and his team are working to change that.

30 Sep 2015

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

Aspen Park Pharmaceuticals, Inc., a private company, today announced that it has acquired worldwide rights from The Ohio State University, through the Ohio State Innovation Foundation, to APP-111. APP-111 is a first-in-class oral, antitubulin targeting agent for the potential treatment for the form of castration resistant prostate cancer that does not respond or becomes resistant to currently available androgen receptor antagonists like XTANDI (enzalutamide) and testosterone reducing agents like ZYTIGA (abiraterone acetate and prednisone).

30 Sep 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Survey: One-third of US women use compounded hormones at menopause

A third of US women who take hormones at menopause are using compounded hormones, shows a new national survey. These women commonly--and mistakenly--think these hormones are safer and offer more benefits than FDA-approved therapies.

30 Sep 2015

Leading cancer researchers address eight 'big questions'

Leading cancer researchers address eight of the "big questions" facing the field as part of the inaugural issue of Trends in Cancer, published by Cell Press.

30 Sep 2015

Mayo Practice Transformation Network selected to participate in Transforming Clinical Practice Initiative

The Mayo Practice Transformation Network is one of 39 health care collaborative networks selected to participate in the Transforming Clinical Practice Initiative, announced today by U.S. Department of Health and Human Services Secretary Sylvia M. Burwell. Mayo Clinic will receive up to $9.7 million to provide technical assistance support to help equip clinicians in the Mayo Practice Transformation Network with tools, information and network support needed to improve quality of care, increase patients' access to information and spend health care dollars more wisely.

30 Sep 2015

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

A gene therapy approach to treating the progressive muscle wasting disorder Duchenne muscular dystrophy (DMD) that does not replace the mutated DMD gene but instead delivers the gene for ITGA7, a protein in skeletal muscle, led to reduced symptoms and significantly extended life span in a mouse model of severe DMD. Over-expression of ITGA7 did not elicit an immune reaction, further supporting its potential as a novel treatment for DMD, according to a new study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

30 Sep 2015

Better support can improve shopping experience for individuals with intellectual disabilities

Better support can greatly improve the supermarket shopping experience for people with intellectual (learning) disabilities, a study by an independent self-advocacy group reveals.

30 Sep 2015

Discrimination leads to dangerous health consequences among transgender Americans

Despite a surge in public attention toward the transgender population, transgender adults continue to face both major and daily discrimination that often directly leads to dangerous health consequences.

30 Sep 2015

Predicting better immunotherapy response, neurological outcomes in adults with autoimmune cerebellar ataxia

While autoimmune cerebellar ataxia (a loss of muscle control coordination) can lead to severe disability with some patients becoming wheelchair-bound, there are factors that may help predict better immunotherapy response, according to the Mayo Clinic study published by JAMA Neurology.

30 Sep 2015

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Patients with autoimmune cerebellar ataxia have better treatment responses and outcomes if they have the nonparaneoplastic form of the condition and are seropositive for neural plasma membrane protein or glutamic acid decarboxylase 65 antibodies, suggests research.

29 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

Therapy News and Research

Researchers discover new way to stop cancer cells from spreading

Postmenopausal women who are not aware of VVA consequences continue to experience pain during sex

Advanced targeted therapies dominate treatment pipeline for colorectal cancer, finds Frost & Sullivan

Multicenter study shows Monteris’ NeuroBlate System improves outcome in brain tumor patients

Research shows more than 30,000 women die from cardiovascular disease in UK

Patients with advanced lung cancer receive more than recommended number of radiation therapy

Oraya therapy is effective in maintaining vision with reduced injections for wet AMD patients

Brodalumab therapy achieves 100% reduction in psoriasis symptoms

UH researcher investigates two new avenues for detection, treatment of prostate cancer

Aspen Park Pharmaceuticals acquires worldwide rights to APP-111 therapy from Ohio State University

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Survey: One-third of US women use compounded hormones at menopause

Leading cancer researchers address eight 'big questions'

Mayo Practice Transformation Network selected to participate in Transforming Clinical Practice Initiative

New gene therapy approach to treating DMD reduces symptoms, extends life span in mouse model

Better support can improve shopping experience for individuals with intellectual disabilities

Discrimination leads to dangerous health consequences among transgender Americans

Predicting better immunotherapy response, neurological outcomes in adults with autoimmune cerebellar ataxia

Serologic status and autoimmune cerebellar ataxia type predict treatment response

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News